Anzeige
Mehr »
Login
Dienstag, 07.05.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Diese Aktie hebt ab: +130,67% Kursgewinn in 1 Monat – das sind die Gründe
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
579 Leser
Artikel bewerten:
(2)

Institut Jules Bordet Invests in Elekta's Latest Cancer Treatment Technology

Renown Belgian hospital to acquire Elekta Unity MR-Linac and Versa radiation therapy systems

BRUSSELS, Jan. 20, 2020 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it signed a contract with the Institut Jules Bordet, Brussels, for an Elekta Unity MR-linac system, two Versa HD linear accelerators (linacs), upgrade of existing Elekta Infinity linacs as well as upgrades and expansions of Monaco treatment planning software and MOSAIQ oncology information systems and service. The total contract is valued at approximately EUR 22 million, of which EUR 18 million will be booked in the third quarter of Elekta's fiscal year 2019/20. The remainder will be booked successively over the next ten years. Elekta won the contract through a public procurement procedure.

Elekta's Head of Region Europe, Renato Leite, says: "We are proud to strengthen our long-standing relationship with the Bordet Institute, which is devoted entirely to patients affected by cancer. As it prepares to move to its New Bordet Institute in 2021, we are excited to be providing the most modern radiotherapy treatment solutions available so the Institute can offer its cancer patients personalized precision radiation medicine."

The comprehensive cancer center is gearing up for its new cancer clinic with an investment in state-of-the-art technology and upgrades to existing devices. This includes Elekta Unity, a transformative magnetic resonance radiation therapy (MR/RT) system, which combines a high-field MRI scanner with a best-in-class linear accelerator to enable personalized precision radiation therapy.

The institute already enjoys Elekta solutions, including Leksell Gamma Knife Icon and two Elekta Infinity linacs as well as MOSAIQ and Monaco and Elekta's microSelectron brachytherapy afterloading platform. The two Versa HD systems in this contract will replace competing systems. When all the solutions will have been deployed the Jules Bordet Institute will be Belgium's the largest single radiation therapy site with four Elekta linacs, one Unity MR-Linac and one Leksell Gamma Knife.

Software upgrades are scheduled for delivery during 2020 and the linear accelerators, including Unity, in 2021.

For further information, please contact:
Oskar Bosson, Global EVP Corporate Communications and Public Affairs
Tel: +46 70 410 7180, e-mail: Oskar.Bosson@elekta.com
Time zone: CET: Central European Time

Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 20:00 CET on January 20, 2020. (REGMAR)

About Elekta Unity
Elekta Unity is a state-of-the art MR-linac that is defining a new standard for personalized radiation therapy based on real-time high resolution anatomical and biological MRI at the point-of-care. Unity combines a Philips high-field 1.5T MRI scanner with a best-in-class 7MV linear accelerator and breakthrough online dose replanning software that are fully integrated to enable adaptive radiotherapy and real-time target monitoring.

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

CONTACT:

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/elekta/r/institut-jules-bordet-invests-in-elekta-s-latest-cancer-treatment-technology,c3012235

The following files are available for download:

https://mb.cision.com/Main/35/3012235/1177017.pdf

Release

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2020 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.